

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50111/043002
	Serial No.	09/215,163
	Applicant	Stinson et al.
	Filing Date	December 18, 1998
	Group	1645
IDS Filed	October 30, 2007	

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Bose et al., "High affinity mouse-human chimeric Fab against Hepatitis B surface antigen," <i>World J. Gastroenterol.</i> 11: 7569-7578 (2005).
	Edwards et al. Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies against escherichia coli toxins Stx1 and Stx2. In: Kaper J., O'Brien A. D., editors. <i>Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli Strains</i> . ASM Press, Washington (DC) 388-392 (1998).
	Morrison, "With FDA talks stalled, Thallion looks abroad," <i>BioWorld Today</i> 18: 1-7 (2007).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	